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Abstract
Coronary in stent restenosis remains a significant limitation to the long term efficacy of coronary artery stent
placement. In this review the authors review the pathophysiology of coronary in stent restenosis, together with an
overview of the current treatment modalities. The potential clinical utility of nanotechnology is also reviewed.
The first human safety trial of systemic nanoparticle paclitaxel (nab-paclitaxel) for in stent restenosis (SNAPIST-I) is
discussed. The results showed no significant adverse advents attributable to the nab-paclitaxel at 10 or 30 mg/m
2,
although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher
doses. No major adverse cardiac events were recorded at 2 months, whilst at 6 months, 4 target lesions required
revascularisation. The investigators concluded therefore that systemic nab-paclitaxel was well tolerated at a dose of
<70 mg/m
2. To date however, no formal clinical evaluation has been reported as to the clinical utility of nab-
paclitaxel, or any of the nano preparations discussed, for the suppression of coronary in stent restenosis.
1. Introduction: Overview of Nanomedicine
Applications in Cardiology
Cardiovascular disease, including acute coronary syn-
dromes and cerebrovascular events continue to be a
major source of mortality and morbidity. Current medi-
cal screening and diagnosis is limited and many of the
symptoms and signs of cardiovascular and cerebrovascu-
lar disease are non-specific.
Nanomedicine provides a unique opportunity to
explore at a cellular or organ level the various pathophy-
siologies of the cardiovascular system. Nanomolecules
have been used in:
￿ Assessing and treating atherosclerosis in asympto-
matic patients
￿ Coronary revasculariation
￿ Thrombolytic therapy
￿ Treatment of coronary in stent restenosis.
2. The use of Nanotechnology for the Treatment
of Coronary In Stent Restenosis
There is still a significant requirement for a novel drug
delivery mechanism for the treatment of coronary in
stent restenosis, due to the limitations of the current
modalities including late stent thrombosis.
A nanoparticle based approach is ideal for the treat-
ment of restenosis since targeted delivery of nanoparti-
cles is feasible and much lower concentrations of the
active drug can be used hence reducing systemic
toxicity.
The size of particle however is critical in the distribu-
tion of nanoparticles in the blood vessel wall. Westedt
et al [1], in experiments conducted using the aorta
abdominalis of New Zealand White Rabbits as a model
system, report that nanoparticles of 100 and 200 nm are
able to penetrate to the inner layers of the vessel wall,
while 514 nm particles accumulate predominantly at the
luminal surface.
Some examples of nanoparticles used in the treatment
of in stent restenosis are reviewed below.
3.1 Lipid Based Nanoparticles
Liposomes are small and have a spherical shape and are
formed from natural and non-toxic phospholipids and
cholesterol. As liposomes are small and posses hydro-
phobic and hydrophilic characteristics there are ideally
suited to the development of novel drug delivery sys-
tems [2]. Liposome surfaces can be modified to increase
circulating half-life and conjugated to antibodies or
ligands for enhanced tissue specificity.
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a number of different classes of drug to the arterial
endothelium.
Clodronate, a bisphonsphonate, has been delivered
using liposome nanoparticle of 1:3 distearoyl phosphati-
dylglycerol, 1, 2 distearoly-sn-gylcero-3-phosphcholine
[3]. Lyposomal choldronate inhibited neointimal growth
in the balloon injured rabbit carotid artery after systemic
administration. Other members of the bisphosphonate
class of drugs including pamidronate and alendronate
have been utilised as antirestenotic agents in balloon
injured rat carotid artery model [4]. It is noteworthy,
however, that these experiments were performed in a
carotid artery model and whether the results are rele-
vant to coronary restenosis after PCI remains unknown.
TRM 484 consists of nanoparticles of prednisolone
with high infinity to chrondroitin suphate proteoglycans
and at a dose of 1 mg/kg significantly reduced neo inti-
mal growth in atherosclaratic New Zealand White Rab-
bits implanted with bare metal stents [5].
3.2 Polymeric based nanoparticles
These are solid, colloidal particles of macromolecules
that range in size from 10-1000 nm [6]. They are idea
drug delivery systems [7], where the compound of inter-
est may be dissolved, entrapped, adsorbed, attached or
encapsulated into the nanoparticle matrix [8,9].
Early work on polymeric nanoparticles began with a
comparison of probucol delivery by polymeric and lipo-
somal nanoparticles. Probucol has been shown to reduce
restenosis after angioplasty provided oral administration
is commenced one month before the procedure [10].
Klughertz and colleagues prepared
35S-probucol incap-
sulated in either liposomal or polylactic-coglycolic acid
(PLGA) nanoparticles, which were delivered using an
infusion catheter after balloon angioplasty of rabbit iliac
arteries. Iliac arteries, perivascular fat and downstream
tissues were harvested and the radioactivity measured
from animals euthanized on day 0,3 and 7 after dosing.
The results showed after delivery efficiency was superior
with PLGA [10]. It should be noted however that these
experiments were conducted outside the coronary
circulation.
Cohen Sela et al reported that PLGA nanoparticles
containing alendronate reduced neointimal formation
and restenosis by systemic transient depletion of mono-
cytes in hypercholesterolaemic rabbit model [11].
Further work by the same group reported incorporation
of the bisphosphonates, 2-(2-Aminopyrimidino) ethyl-
diene-1, 1-bisphosphonbic acid betaine (ISA) into PLGA
based nanoparticles (ISA - NP) [12]. Intravenously
administered ISA-NP resulted in a significant attenua-
tion of restenosis by 45%, 14-days after carotid artery
injury in comparison to a control group of animals
treated with free ISA, buffer or blank nanoparticles.
However, the effect was not preserved long-term (30-
days post injury) and no significant reduction in neointi-
mal reduction was observed. Surprisingly, significant
neointimal suppression was observed following subcuta-
neous injection of ISA-NP [12].
Paclitaxel is a member of the taxane family of drugs.
Paclitaxel loaded nanoparticles have been prepared from
oil-water emulsion using biodegradable PLGA and sur-
face modified with the cationic surfactant didoceyl-
methylammonium bromide (DMAB) to enhance arterial
retention. In vivo investigations have been performed in
balloon injured rabbit carotid arteries treated with a sin-
gle infusion of paclitaxel loaded nanoparticles and
observed for 28 days. The results demonstrated that the
inhibitory effect on intimal proliferation was dose
dependant, and at 30 mg/ml nanoparticle concentration,
completely inhibited intimal proliferation, leading the
group to speculate that the surface modified paclitaxel
loaded nanoparticles provide an effective means of inhi-
biting the proliferative response to vascular injury [13].
Further results by Westedt et al [14] substantiated these
findings utilising paclitaxel-loaded nanoparticles admi-
nistered locally to the wall of balloon injured rabbit iliac
arteries using a porous balloon catheter. The results
demonstrated a 50% reduction in neointimal area com-
pared to the control vessels treated with blank
nanoparticles.
Work from another group has demonstrated that the
antiproliferative effects of paclitaxel can be significantly
improved by co-administration of other agents [15]. C6-
ceramide is an apoptotic signalling molecule and has
been combined with paclitaxel in polymeric nanoparti-
cles consisting of poly(ethylene oxide) - modified poly
(episilon caprolactone). Combination of paclitaxel with
cereamide when administered in nanoparticle formula-
tion significantly augmented the antiproliferative effect
of either agent alone [15].
The angiotensin-converting-enzyme inhibitor, lisino-
pril, has also been encapsulated in nanoparticles of
P L G Af o rs i t es p e c i f i cd e l i v e r yb yc a t h e t e r sf o rt h ep r e -
vention of coronary in stent restenosis [16], although to
date in-vivo studies to examine the anti-restenotic effect
have not been reported.
Further work from Cohen-Sela’s group [17] incorpo-
rated the antiproliferative agent mitramycin into PLGA
nanoparticles using a nanoparticipation technique.
Unfortunately in-vivo testing using a rat carotid artery
model showed no inhibition of restenosis. The authors
suggest that this is probably due to the short depletion
period of circulating monocytes and the lack of arterial
targeting.
Work to increase the bioadhesive properties of nano-
particles has been suggested to improve retention and
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[18]. Zou et al [18] prepared bioadhesive PLGA nano-
particles, encapsulating rapamycin, using different con-
centration of carbopol 940, however in-vivo results are
awaited.
Recent research has focused on the administration of
drugs using biodegradable polymer nanoparticles cap-
able of prolonged drug release. Sustained drug release of
dexamethasone or rapamycin from nanoparticles based
on poly (ethylene oxide) and poly (d.L-lactic-co-glycolic
acid) block copolymers has been investigated [19]. The
investigators found that treating the nanoparticles with
gelatine or albumin after drug loading resulted in a lin-
ear drug release, the rate of release being related to the
amount of protein associated with the nanoparticles
[19]. Release of dexamethasone and rapamycin was sus-
tained for 17 and 50 days respectively [19].
Luderer et al [20] report the use of sirolimus loaded
biodegradable poly (D,L lactide) nanoparticles as drug
carriers to prevent restenosis following coronary angio-
plasty [20]. The particles showed a biphasic release pat-
tern consisting of a short burst release of 50% w/w
sirolimus followed by a longer slower release.
Moreover, Nakano et al [21] have succeeded in for-
mulating a nanoparticle eluting stent. In a porcine cor-
onary artery model, the magnitude of stent induced
injury, inflammation, endothelial recovery and neointi-
mal formation were comparable between bare metal
stent and nanoparticle eluting stent. It is worthy of note,
however, that the study neither presents data on reste-
n o s i sr a t en o rt h ei n c o r p o r a tion of any pharmaceutical
preparations within the nanoparticles.
The tryphostins are a class of platelet derived growth
factor (PDGF) receptor b tyrosine kinase blockers
[22,23]. Preclinical investigations have reported results
with the experimental compound AG-1295 incorporated
in polylactide nanoparticles. PLA AG-1295 nanoparticles
were delivered via an infusion catheter in a balloon
injured swine model, resulting in inhibition of smooth
muscle cell (SMC) growth. Further, another tyrphostin
AGL-2043 encapsulated in in PLA nanoparticles inhib-
ited restenosis in both balloon injured rat carotid artery
and stented porcine artery models [24].
3.3 Gel like Nanoparticles
Previous research [25] has demonstrated that nanosized
(100 nm) hydrogel spheres made of poly (N-isopropyla-
crylamide) are internalised by endothelial cells and
VSMC more than microspheres (1 μm), although cellu-
lar uptake was dependant on the incubation time,
sphere concentration and introduced shear stress levels
of the medium. In contrast, microspheres were rapidly
taken up by phagocytes, especially at high concentration
[25]. These findings lead the authors to suggest that
hydrogel nanospheres are more effective as an intravas-
cular delivery system in terms of vascular uptake and
biocompatibility [25].
Since significant number of VSMC undergo rapid
apoptosis following balloon angioplasty Reddy and col-
leagues [26] tested the hypothesis that preventing
VSMC from apoptosis could prevent intimal hyperplasia.
They used rapamycin (which has anti-apoptotic and
antiproliferative actions) loaded gel nanoparticles of
mean diameter 54 nm. When infused into a rat carotid
artery model of vascular injury the authors report signif-
icant inhibition of hyperplasia and re-endothelialisation
of the injured artery. Further, the group report inhibi-
tion of activation of caspase 3/7 enzyme systems in the
treated artery, preventing VSMC from undergoing apop-
tosis [26]
3.4 Miscellaneous Studies
Kolodgie et al [27] report the preparation of paclitaxel
loaded albumin based nanoparticles for the reduction of
in stent neointimal growth. The research conducted in
New Zealand White Rabbits receiving bilateral iliac
artery stents yielded significant results. Systemic admin-
istration of albumin nanoparticles containing paclitaxel
reduced neointimal growth at 28 days. A further single
repeated dose was required for sustained neointimal
suppression at 90 days post procedure [27].
Moreover, further preclinical work has demonstrated
the utility of tissue factor targeted nanoparticles contain-
ing doxorubicin or paclitaxel to inhibit VSMC prolifera-
tion in culture [28].
In addition, intra mural delivery of aVb3-targeted
rapamycin loaded nanoparticles inhibited stenosis with-
out delaying endothelial healing after balloon injury [29].
Chorney et al [30] report the use of uniform magnetic
fields to control the release of paclitaxel from biocompa-
tible magnetic nanoparticles. The research showed that
magnetic treatment of cultured arterial SMC with pacli-
taxel loaded magnetic nanoparticles caused significant
inhibition of cell growth, which was not observed under
non-magnetic conditions. The authors postulate that the
r e s u l t sd e m o n s t r a t et h ef e a s i b i l i t yo fs i t es p e c i f i cd r u g
d e l i v e r yb yu n i f o r mf i e l dc o n trolled targeting of mag-
netic nanopatticles [30].
3.5 Clinical Study
To date only one human study has been reported in the
literature. In 2007, Margolis et al [31] presented the
first human safety trial of systemic nanoparticle pacli-
taxel (nab-paclitaxel) for in stent restenosis I (SNAPIST-
I). In this study the investigators administered systemic
treatment with a 130 nm albumin nanoparticle encapsu-
lating paclitaxel in 10, 30, 70 and 100 mg/m
2 intrave-
nously after stenting of a single lesions of ≥ 3m mi n2 3
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events attributable to the nab-paclitaxel at 10 or 30 mg/
m
2, although moderate neutropenia, sensory neuropathy
and mild to moderate reversible alopecia occurred at
higher doses. No major adverse cardiac events were
recorded at 2 months, whilst at 6 months 4 target
lesions required revascularisation. The investigators con-
cluded therefore that systemic nab-paclitaxel was well
t o l e r a t e da tad o s eo f< 7 0m g / m
2 [31]. To date however
no formal clinical evaluation has been reported as to the
clinical utility of nab-paclitaxel for the suppression of
coronary in stent restenosis.
4. Conclusion
Much work therefore has been undertaken to evaluate
the potential clinical utility of nanoparticles for the tar-
geted and non-targeted delivery of various agents with
antiproliferative and anti-restenostic actions. To date
most of these investigations have been conducted either
in-vitro or in-vivo utilising animal models. Many studies
have also been conducted outside the coronary circula-
tion and hence the relevance of the result to coronary
in stent restenosis can only be postulated. To date only
one human study has been reported. This was a dose
ranging study demonstrating that systemic nab-pacli-
taxel was well tolerated at a dose of <70 mg/m
2 [23].
No formal clinical evaluation has been reported as to
the clinical utility of nab-paclitaxel for the suppression
of coronary in stent restenosis.
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